ES2432082T3 - Uso de la variante de corte y empalme MGF del factor de crecimiento I similar a la insulina para la prevención del daño miocárdico - Google Patents
Uso de la variante de corte y empalme MGF del factor de crecimiento I similar a la insulina para la prevención del daño miocárdico Download PDFInfo
- Publication number
- ES2432082T3 ES2432082T3 ES03737378T ES03737378T ES2432082T3 ES 2432082 T3 ES2432082 T3 ES 2432082T3 ES 03737378 T ES03737378 T ES 03737378T ES 03737378 T ES03737378 T ES 03737378T ES 2432082 T3 ES2432082 T3 ES 2432082T3
- Authority
- ES
- Spain
- Prior art keywords
- polypeptide
- mgf
- polynucleotide
- fgm
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0202906 | 2002-02-07 | ||
| GBGB0202906.4A GB0202906D0 (en) | 2002-02-07 | 2002-02-07 | Prevention of myocardial damage |
| PCT/GB2003/000537 WO2003066082A1 (en) | 2002-02-07 | 2003-02-06 | Use of the insulin-like-growth factor i splice variant mgf for the prevention of myocardial damage |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2432082T3 true ES2432082T3 (es) | 2013-11-29 |
Family
ID=9930632
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES03737378T Expired - Lifetime ES2432082T3 (es) | 2002-02-07 | 2003-02-06 | Uso de la variante de corte y empalme MGF del factor de crecimiento I similar a la insulina para la prevención del daño miocárdico |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US20050048028A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1480669B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2005516997A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2003244511A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK1480669T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2432082T3 (cg-RX-API-DMAC7.html) |
| GB (1) | GB0202906D0 (cg-RX-API-DMAC7.html) |
| PT (1) | PT1480669E (cg-RX-API-DMAC7.html) |
| WO (1) | WO2003066082A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0202906D0 (en) | 2002-02-07 | 2002-03-27 | Univ London | Prevention of myocardial damage |
| WO2006097682A1 (en) * | 2005-03-18 | 2006-09-21 | Ucl Business Plc | Mechano growth factor peptides and their use |
| CA2601227A1 (en) * | 2005-03-18 | 2006-09-21 | Ucl Business Plc | Mecano growth factor peptides and their use |
| CL2007001614A1 (es) | 2006-06-09 | 2008-08-08 | Novartis Ag | Polipeptido que comprende una proteina del precursor del factor de crecimiento tipo insulina, igf-1 humana, en la cual la escision del peptido e mediante una proteasa se reduce a traves de la modificacion de la proteina del precursor; y su uso para t |
| WO2009012443A1 (en) * | 2007-07-18 | 2009-01-22 | The Board Of Trustees Of The University Of Illinois | Nanoparticles for the elution of growth factors for recovery and regeneration of organs |
| CN101891812B (zh) * | 2010-07-09 | 2012-10-17 | 山西大学 | 力生长因子多肽及其制备方法和用途 |
| CN103031277B (zh) * | 2011-09-29 | 2015-07-15 | 重庆大学 | 力生长因子在制备无血清培养耐受型哺乳动物工程细胞中的应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2460147C2 (de) | 1974-12-19 | 1983-05-05 | Ibm Deutschland Gmbh, 7000 Stuttgart | Anordnung zur Dekomprimierung komprimierter Information für aus schwarzen und weißen Bereichen zusammengesetze darzustellende Zeichen |
| US4732863A (en) | 1984-12-31 | 1988-03-22 | University Of New Mexico | PEG-modified antibody with reduced affinity for cell surface Fc receptors |
| US4963665A (en) | 1986-01-07 | 1990-10-16 | Washington University | Human preproinsulin-like growth factor I |
| US5080891A (en) * | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
| SE8703625D0 (sv) * | 1987-09-18 | 1987-09-18 | Kabivitrum Ab | New medical use |
| US5122614A (en) * | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| US5652214A (en) * | 1989-06-05 | 1997-07-29 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factors and analogs |
| US5194596A (en) * | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
| DK0437563T3 (da) | 1989-08-07 | 1995-05-29 | Debio Rech Pharma Sa | Bioligiske aktive lægemiddelpolymerderivater |
| US5350836A (en) * | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
| SE9100099D0 (sv) | 1991-01-11 | 1991-01-11 | Kabi Pharmacia Ab | Use of growth factor |
| SE9101341D0 (sv) | 1991-05-03 | 1991-05-03 | Kabi Pharmacia Ab | New medicinal use |
| ES2101865T3 (es) * | 1991-08-01 | 1997-07-16 | Genentech Inc | Igf-1 para mejorar el estado neural. |
| US5861373A (en) * | 1991-08-01 | 1999-01-19 | Genentech, Inc | IGF-1 to improve the neural condition |
| US5298422A (en) | 1991-11-06 | 1994-03-29 | Baylor College Of Medicine | Myogenic vector systems |
| CA2123685C (en) | 1991-11-25 | 2003-10-07 | Hans-Arne Hansson | Medicament for promoting growth of mammalian nerve |
| FR2687681B1 (fr) * | 1992-02-20 | 1995-10-13 | Transgene Sa | Conjugues polyethyleneglycol-hirudine, leur procede de preparation et leur emploi pour le traitement des thromboses. |
| US5840900A (en) * | 1993-10-20 | 1998-11-24 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
| WO1995013290A1 (en) | 1993-11-12 | 1995-05-18 | North Shore University Hospital Research Corporation | Method of treating muscular dystrophy |
| US5730990A (en) * | 1994-06-24 | 1998-03-24 | Enzon, Inc. | Non-antigenic amine derived polymers and polymer conjugates |
| US5650496A (en) * | 1995-04-14 | 1997-07-22 | Cephalon, Inc. | IGF-I purification process |
| GB9605124D0 (en) * | 1996-03-11 | 1996-05-08 | Royal Free Hosp School Med | Method of treating muscular disorders |
| US6214966B1 (en) * | 1996-09-26 | 2001-04-10 | Shearwater Corporation | Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution |
| PT1075282E (pt) | 1998-04-28 | 2005-09-30 | Applied Research Systems | Conjugados analogos de peg-lhrh |
| GB9926968D0 (en) | 1999-11-15 | 2000-01-12 | Univ London | Treatment of neurological disorders |
| GB0011278D0 (en) * | 2000-05-10 | 2000-06-28 | Univ London | Repair of nerve damage |
| GB0202906D0 (en) | 2002-02-07 | 2002-03-27 | Univ London | Prevention of myocardial damage |
| GB0203552D0 (en) | 2002-02-14 | 2002-04-03 | Beaumont Nicholas J | Peptide growth factor |
| WO2006097682A1 (en) | 2005-03-18 | 2006-09-21 | Ucl Business Plc | Mechano growth factor peptides and their use |
-
2002
- 2002-02-07 GB GBGB0202906.4A patent/GB0202906D0/en not_active Ceased
-
2003
- 2003-02-06 PT PT37373784T patent/PT1480669E/pt unknown
- 2003-02-06 ES ES03737378T patent/ES2432082T3/es not_active Expired - Lifetime
- 2003-02-06 EP EP03737378A patent/EP1480669B1/en not_active Expired - Lifetime
- 2003-02-06 JP JP2003565505A patent/JP2005516997A/ja active Pending
- 2003-02-06 US US10/504,078 patent/US20050048028A1/en not_active Abandoned
- 2003-02-06 AU AU2003244511A patent/AU2003244511A1/en not_active Abandoned
- 2003-02-06 WO PCT/GB2003/000537 patent/WO2003066082A1/en not_active Ceased
- 2003-02-06 DK DK03737378.4T patent/DK1480669T3/da active
-
2007
- 2007-03-20 US US11/723,493 patent/US20080039390A1/en not_active Abandoned
-
2012
- 2012-09-21 US US13/624,365 patent/US9919031B2/en not_active Expired - Fee Related
-
2018
- 2018-03-13 US US15/920,361 patent/US20180271942A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US9919031B2 (en) | 2018-03-20 |
| DK1480669T3 (da) | 2013-05-06 |
| JP2005516997A (ja) | 2005-06-09 |
| US20130210723A1 (en) | 2013-08-15 |
| EP1480669A1 (en) | 2004-12-01 |
| US20080039390A1 (en) | 2008-02-14 |
| AU2003244511A1 (en) | 2003-09-02 |
| EP1480669B1 (en) | 2013-01-23 |
| PT1480669E (pt) | 2013-05-22 |
| WO2003066082A1 (en) | 2003-08-14 |
| US20180271942A1 (en) | 2018-09-27 |
| GB0202906D0 (en) | 2002-03-27 |
| US20050048028A1 (en) | 2005-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2013287281B2 (en) | AAV-mediated gene therapy for RPGR x-linked retinal degeneration | |
| US20180271942A1 (en) | Use of the Insulin-Like-Growth Factor 1 Splice Variant MGF for the Prevention of Myocardial Damage | |
| JP6046493B2 (ja) | プロミニン−1の血管新生促進フラグメントおよびその使用 | |
| KR20220107243A (ko) | Apoe 유전자 요법 | |
| CN116685329A (zh) | 核酸构建体及其用于治疗脊髓性肌肉萎缩症的用途 | |
| JP7575273B2 (ja) | デュシェンヌ型筋ジストロフィーを治療するための組成物及び方法 | |
| ES2936383T3 (es) | Terapias basadas en transcriptasa inversa de la telomerasa para el tratamiento de afecciones asociadas con el infarto de miocardio | |
| US20060058239A1 (en) | Use of the insulin-like-growth factor I isoform MGF for the treatment of neurological disorders | |
| ES2864731T3 (es) | Terapias a base de la telomerasa transcriptasa inversa | |
| KR102236843B1 (ko) | 새로운 재생 치료제로서의 camkk1 | |
| EP1967210A1 (en) | Novel application of apelin | |
| US8865669B2 (en) | DNA fragment and use thereof | |
| WO1999010013A1 (en) | The use of insulin-like growth factor-i in muscle | |
| US6723707B1 (en) | Use of insulin-like growth factor-I in muscle | |
| CN103127492A (zh) | 一种抗丙型肝炎病毒的蛋白及其用途 | |
| WO2015153357A1 (en) | Compositions and methods for improving cardiac function | |
| CN115666624A (zh) | 作为抗癌治疗的emid2蛋白 | |
| WO2025240625A1 (en) | Cbin1 therapy improves atrial electrical and functional remodeling, limiting atrial arrhythmias in failing hearts | |
| JP2002051786A (ja) | 骨・軟骨形成組織特異的なプロモーター及びその利用 | |
| Harper et al. | MUSCLE AND CONNECTIVE TISSUE | |
| HK40049102A (en) | Compositions and methods for treating duchenne muscular dystrophy | |
| JP2016131541A (ja) | トランスジェニック非ヒト哺乳動物及びその用途 | |
| JP2013531990A (ja) | アテローム性動脈硬化症治療のための組成物および方法 |